Nanoparticles have shown a certain potential to overcome the drawbacks of oral peptide delivery in the gastrointestinal tract such as low peptide stability and permeability. Insulin PLGA NP were prepared using a modified double emulsion solvent evaporation technique. Insulin PLGA NP were composed from human insulin (5 mg) encapsulated in PLGA 2.5% (w/v) mixed with PEG (2kDa, 5% w/w) and the external aqueous phase contained 1.25% of PVA. The resulting nanoparticles of 202.6 nm diameter and loaded with 33.86 μg insulin per mg of polymer were utilised in this study to examine the hypoglycaemic effect after combination with a protease inhibitor, N-Ethylmaleimide.
Diabetes Mellitus; Nanoparticles; Human Insulin; Protease Inhibitor
How to Cite
Faheem, A. M. & Abdeĺkader, D. & A. Osman, M. & A. McCarron, P. & A. El-Gizawy, S., (2019) “Oral Insulin Delivery in Diabetic Rats by PLGA Nanoparticles Combined with a Protease Inhibitor (N-Ethylmaleimide)”, British Journal of Pharmacy 4(1). doi: https://doi.org/10.5920/bjpharm.588